Refractory Anemia With Excess of Blasts (RAEB)

DBCOND0054529Hemic and Lymphatic DiseasesNeoplasms

Refractory Anemia With Excess of Blasts (RAEB) is the indication for 3 drugs in DrugBank. It is covered by 4 curated, structured indications.

Also known as
Refractory anaemia with an excess of blasts · Refractory anemia with an excess of blasts · Refractory Anemia With Excess Blasts · Anemia, Refractory, With Excess of Blasts · Myelodysplastic Syndrome-Refractory Anemia With Excess Blasts
Classified under
Indicated drugs

Resolves to

Vocabularies
MeSHM0001139ICD-10D46.2SNOMED CT109999001MedDRA10037803UMLSC0002894

What you can answer from here — as of October 31, 2026

3Indicated drugsWith each drug's targets and mechanism
Listed above
4Structured indicationsPopulation, line of therapy, route and combination as fields, not prose
Sign in
287Clinical trialsPhase, status and sponsor resolved per trial
Sign in

Which approved drugs for Refractory Anemia With Excess of Blasts (RAEB) share a target, and which companies have late-stage candidates against it?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In